Search

Blue internal teat sealant now in dairy mastitis portfolio

Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio

Boehringer Ingelheim announces 2018 BVDzero Case Awards

Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com

Animal Health Collaboration with Novozymes

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D

BI Focuses COVID-19 Clinical Research on Alteplase

BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems

2021 PRRS Research Award winners announced

The 2021 European PRRS Research Award winners announced

First Translational Medicine Award awarded

The Award recognizes the research that has the highest translational potential

Partnership Boehringer Ingelheim Lifebit health data

Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data

U.S. FDA grants priority review for spesolimab in GPP

U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis

2020 European PRRS Research Award sponsorship

2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions

ATM-Ranking-2021

Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.

bix_facilitates_global_partnerships

BI X focuses on partnerships to speed up the development of digital healthcare solutions

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines

PREVEXXION® RN: Marek’s disease vaccine available in EU UK

Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.

Stem cell therapy for tendon and ligament injuries in horses

A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.

FRONTLINE® becomes Brand of the Year 2021-22

FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards

LastMile increases access to veterinary care in Africa

Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial

FIBRONEER™ Phase III program initiated

FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor